Cerity Partners LLC Purchases Shares of 1,909 United Therapeutics Co. (NASDAQ:UTHR)

Cerity Partners LLC purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 1,909 shares of the biotechnology company’s stock, valued at approximately $420,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. C M Bidwell & Associates Ltd. bought a new position in United Therapeutics during the 3rd quarter valued at $91,000. Blue Trust Inc. boosted its stake in United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 46 shares in the last quarter. Synovus Financial Corp bought a new position in United Therapeutics during the 3rd quarter valued at $203,000. Caxton Associates LP bought a new position in United Therapeutics during the 3rd quarter valued at $213,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in United Therapeutics during the 3rd quarter valued at $219,000. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Nilda Mesa sold 325 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total transaction of $77,285.00. Following the completion of the sale, the director now directly owns 5,373 shares in the company, valued at $1,277,699.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Christopher Patusky sold 1,680 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $224.00, for a total transaction of $376,320.00. Following the completion of the sale, the director now directly owns 4 shares in the company, valued at $896. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Nilda Mesa sold 325 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total value of $77,285.00. Following the sale, the director now owns 5,373 shares of the company’s stock, valued at $1,277,699.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 136,990 shares of company stock worth $32,239,641. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $235.95 on Friday. The stock has a market cap of $11.10 billion, a PE ratio of 11.89 and a beta of 0.52. The business has a fifty day simple moving average of $233.36 and a 200-day simple moving average of $228.79. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping the consensus estimate of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. United Therapeutics’s revenue was up 25.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.67 earnings per share. On average, sell-side analysts anticipate that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company raised their price objective on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th. Wedbush reissued an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. SVB Leerink assumed coverage on United Therapeutics in a research note on Monday, February 5th. They set an “outperform” rating and a $330.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $294.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.